SAFC Expands Continuous Flow Capabiliti?es for Research and Commercial Scale
Sigma-Aldrich Corporation has announced that SAFC Commercial, its custom manufacturing services business unit, has installed a new commercial-scale continuous flow reactor at its Sheboygan, Wis., facility with capacity to produce up to 150 kg of product per day. Now fully operational, the reactor is complemented by a smaller pilot-scale continuous flow reactor that is being fabricated at the nearby Milwaukee, Wis., facility to carry out process optimization studies and manufacturing capability of up to 30 kg of product per day.
“SAFC has invested in making these unique capabilities available to give customers access to products synthesized through reactions that were previously impractical or impossible to do with a conventional batch platform,” said Andreas Weiler, Director of Global Strategic Marketing for SAFC. “The reactors will allow SAFC to develop or scale up flow reactions for customers, eliminating the need for customers to install in-house flow capacity, saving them a great deal of money, space and time. This is also a much greener technology and substantially reduces the amount of chemicals and solvents employed in reactions.”
Continuous flow manufacturing is a lean manufacturing platform that provides customers access to as little or as much of a product as needed. The nature of this technique offers safer, seamless scale-up of a wider array of reactions compared to the batch platform. Additionally, this technique may aid customers in achieving process control, while helping to eliminate batch failures and minimize risks associated with handling hazardous chemicals.
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.